Steph & Co. Sells 27 Shares of argenx SE (NASDAQ:ARGX)

Steph & Co. lessened its holdings in argenx SE (NASDAQ:ARGX) by 6.7% during the 4th quarter, Holdings Channel reports. The firm owned 374 shares of the company’s stock after selling 27 shares during the period. Steph & Co.’s holdings in argenx were worth $230,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Point72 Hong Kong Ltd acquired a new position in argenx in the second quarter valued at approximately $76,000. Cromwell Holdings LLC lifted its stake in shares of argenx by 73.3% in the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after purchasing an additional 66 shares during the period. GAMMA Investing LLC boosted its position in shares of argenx by 47.5% in the 3rd quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after purchasing an additional 56 shares during the last quarter. Blue Trust Inc. increased its holdings in argenx by 413.9% in the third quarter. Blue Trust Inc. now owns 370 shares of the company’s stock valued at $201,000 after purchasing an additional 298 shares during the last quarter. Finally, Keudell Morrison Wealth Management bought a new stake in argenx in the third quarter valued at about $207,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

ARGX has been the subject of several analyst reports. Raymond James restated a “strong-buy” rating and set a $605.00 target price on shares of argenx in a research report on Thursday, October 10th. Citigroup boosted their price objective on shares of argenx from $512.00 to $635.00 and gave the company a “buy” rating in a report on Thursday, October 17th. Guggenheim increased their target price on shares of argenx from $585.00 to $665.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Deutsche Bank Aktiengesellschaft lowered shares of argenx from a “buy” rating to a “hold” rating in a report on Friday, October 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $717.00 price objective (up previously from $670.00) on shares of argenx in a research note on Tuesday. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $658.39.

argenx Stock Performance

ARGX opened at $665.19 on Thursday. The business’s 50-day simple moving average is $617.93 and its 200 day simple moving average is $553.49. The firm has a market capitalization of $40.16 billion, a PE ratio of -755.90 and a beta of 0.59. argenx SE has a 52-week low of $349.86 and a 52-week high of $678.21.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $588.88 million for the quarter, compared to analysts’ expectations of $543.29 million. During the same quarter in the prior year, the business posted ($1.25) EPS. On average, research analysts forecast that argenx SE will post 2.2 earnings per share for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.